BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor survival, driven in part by early metastatic spread. Conventional imaging lacks sufficient precision to predict metastasis accurately. Machine learning (ML)-bas...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) presents a significant challenge, with a 5-year survival rate of approximately 10%. Tumor heterogeneity contributes to the limited effectiveness of treatments. Several tumor and stroma molecular cla...
Cancer immunology, immunotherapy : CII
Nov 12, 2025
Matrix stiffness is a defining feature of pancreatic ductal adenocarcinoma (PDAC) and drives malignant progression through mechanisms that remain poorly understood. Using an ensemble machine learning approach, we integrated multiomics data from 886 p...
Cancer imaging : the official publication of the International Cancer Imaging Society
Oct 24, 2025
BACKGROUND: To evaluate the feasibility and diagnostic utility of a deep learning (DL)-based super-resolution (SR) reconstruction algorithm applied to pancreatobiliary MRI for assessing pancreatic intraductal papillary mucinous neoplasms (IPMNs).
Early detection of pancreatic ductal adenocarcinoma (PDA) remains a major clinical challenge due to the lack of reliable biomarkers. We developed and validated a machine learning (ML)-based serum protein biomarker panel to enhance PDA diagnosis. Seru...
To evaluate the effectiveness of open-weight large language models (LLMs) in extracting key radiological features and determining National Comprehensive Cancer Network (NCCN) resectability status from free-text radiology reports for pancreatic ducta...
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) continues to have extremely poor patient outcomes, unlike other cancer types which have seen significant improvements in their treatments and survival. A major contributing factor is that PDAC is ...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) and mass-forming pancreatitis (MFP) share similar clinical, laboratory, and imaging features, making accurate diagnosis challenging. Nevertheless, PDAC is highly malignant with a poor prognosis, whe...
The Journal of clinical investigation
Jul 15, 2025
Pancreatic ductal adenocarcinoma (PDAC) is known to progress from one of two main precursor lesions: pancreatic intraepithelial neoplasia (PanIN) or intraductal papillary mucinous neoplasm (IPMN). The poor survival rates for patients with PDAC, even ...
European journal of cancer (Oxford, England : 1990)
Jul 5, 2025
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) frequently presents with occult metastatic disease which can undermine the benefit of local treatment. Improved preoperative tools may enhance risk stratification.
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.